Ruxolitinib 1.5% Topical Cream for the Treatment of Pediatric Alopecia Areata

J Drugs Dermatol. 2024 May 1;23(5):378-379. doi: 10.36849/JDD.7782.ABSTRACTAlopecia areata (AA) is a common autoimmune disorder. Although its pathogenesis is not fully understood, AA involves CD8 T cell-mediated destruction of the hair follicle. Several treatment options exist; however, there is minimal evidence in the pediatric population. Currently, there are no curative treatments for AA. The literature suggests that Janus kinase (JAK) inhibitors may be an effective treat-ment for AA, but evidence in pediatric patients is limited. Here, we report a case of severe pediatric AA treated with topical ruxolitinib, a JAK inhibitor. J Drugs Dermatol. 2024;23(5):378-379. doi:10.36849/JDD.7782.PMID:38709705 | DOI:10.36849/JDD.7782
Source: Journal of Drugs in Dermatology - Category: Dermatology Authors: Source Type: research